Friday, April 24, 2015

Cyramza (ramucirumab) receives Fourth FDA approval

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration (FDA) approval for Cyramza (ramucirumab). Cyramza is now also indicated in combination with FOLFIRI  chemotherapy for the treatment of patients with Metastatic Colorectal Cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
"Cyramza now has approvals in advanced or metastatic forms of three of the world's most common and deadly cancers, gastric, Non-small cell lung, and colorectal, with four FDA approvals received in just over a year," said Sue Mahony, Ph.D., senior vice president and president, Lilly Oncology. "This progress is encouraging and supports our ongoing development program for Cyramza. Achieving today's milestone is another example of Lilly's commitment to people living with gastrointestinal cancers."

No comments:

Post a Comment